乙型肝炎患者和无症状乙肝表面抗原携带者体内的乙肝表面抗原循环免疫复合物（HBsAg-CICs）
Hepatitis B surface antigen circulating immune complexes (HBsAg-CICs) in patients with hepatitis B and asymptomatic HBsAg carriers.
作者信息
Anh-Tuan N, Novák E
出版信息
Clin Exp Immunol. 1981 Feb;43(2):246-53.
The PEG-trypsinization assay detected HBsAg-CICs in 31 out of 44 (70%) patients with acute hepatitis B, in five out of 107 (5%) asymptomatic HBsAg carriers and, in addition, in both patients with HBsAg-positive chronic liver disease. A close correlation between the levels of HBsAg-CICs and disease activity was observed. The clinical course, parameters of liver function tests and outcome of the disease in patients without HBsAg-CICs (group A) and in patients with transient HBsAg-CICs (group B) were essentially similar. In contrast, patients with persistent HBsAg-CICs (group C) had a poor prognosis, particularly those who received corticosteroids. The method appeared to be a valuable tool in monitoring disease activity and prognosis, and in evaluating the efficacy of corticosteroid treatment. The role of HBsAg-CICs in the pathogenesis of liver damage and clearance of circulating HBsAg is discussed.
聚乙二醇胰蛋白酶消化试验在44例急性乙型肝炎患者中的31例（70%）、107例无症状HBsAg携带者中的5例（5%）以及2例HBsAg阳性慢性肝病患者中检测到了HBsAg - 循环免疫复合物（CIC）。观察到HBsAg - CIC水平与疾病活动之间存在密切相关性。无HBsAg - CIC的患者（A组）和短暂出现HBsAg - CIC的患者（B组）的临床病程、肝功能检查参数及疾病转归基本相似。相比之下，持续存在HBsAg - CIC的患者（C组）预后较差，尤其是接受皮质类固醇治疗的患者。该方法似乎是监测疾病活动和预后以及评估皮质类固醇治疗疗效的有价值工具。本文讨论了HBsAg - CIC在肝损伤发病机制及循环中HBsAg清除中的作用。
Zotero 插件